Slide 1: Fiscal Fourth Quarter and Full Year 2025 Financial Results
Conference Call 1 Fiscal Fourth Quarter and Full Year 2025 Financial Results N ove m b e r 21 , 2 0 2 5 1 © 2025 Azenta, Inc. • All rights reserved
Slide 2: Safe Harbor Statement
Safe Harbor Statement “Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward- looking statements that are subject to risks and uncertainties that c
Slide 3: Transformative 2025, with Momentum Heading into 2026
Transformative 2025, with Momentum Heading into 2026 • Q4’25 revenue growth of 6% reported and 4% organic Q4 & FY’25 Results • FY’25 organic revenue growth of 3% and Adjusted EBITDA margin expansion of 310bps • Organic revenue growth expected to be 3%–5% YoY FY’26 Guidance • Deliver 300bps of Adjust
Slide 4: Azenta Life Sciences Q4 & FY 2025 Financial Overview
Azenta Life Sciences Q4 & FY 2025 Financial Overview Continuing Operations – Quarter and Year Ended September 30, 2025 Balance Sheet and Revenue (YoY) Profitability Capital Allocation • Q4 revenue $159M, up 6% reported and • Non-GAAP EPS of $0.21 in Q4 and • Strong balance sheet with cash balance 4%
Slide 5: Azenta Operating Performance
Azenta Operating Performance Continuing Operations – Quarter and Year Ended September 30, 2025 Total Azenta Organic Growth Q1’24 Revenue Growth (YtY) $ millions except EPS and percentages $ millions Non-GAAP Non-GAAP Azenta | Q4'25 QTD Q4'24 Q4'25 YtY FY'24 FY'25 YtY Q4'24 Q4'25 YtY Revenue $ 151 $
Slide 6: Q4 2025 Revenue Summary
Q4 2025 Revenue Summary Organic unless otherwise noted Sample Management Solutions Sample Management Solutions 54% (“SMS”) • MSD growth in Sample Storage • $86 million • 2% % YoY reported • Core Products flat YoY: • Flat YoY organic • Strength in C&I, Automated Stores and • $159 million Clinical Bio
Slide 7: Summary Consolidated Balance Sheet
Summary Consolidated Balance Sheet Year Ended September 30, 2025 Balance Sheet Q1’24 Revenue Growth (YtY) Highlights $ millions Jun Sep 2025 2025 QtQ Cash, restricted cash, short term marketable securities 321 343 22 • B Medical assetsQ1'23 and liabilities are presented Q1'24 YtYas Accounts receivab
Slide 8: Summary Consolidated Cash Flow
Summary Consolidated Cash Flow Year Ended September 30, 2025 Cash Flow Q1’24 Revenue Growth (YtY) Highlights $ millions Q4'25 • $559M of cash, Q1'23 cash equivalents, Q1'24restrictedYtY cash Cash, restricted cash and marketable securities - Beginning 565 and marketable securities, including $13M in
Slide 9: Fiscal Year 2026 Guidance
Fiscal Year 2026 Guidance Metric FY’2026 Organic Growth: 3% to 5% YoY Revenue Multiomics: LSD Sample Management Solutions: MSD Adjusted Approximately 300bps of Adjusted EBITDA EBITDA margin expansion Free cash flow improvement of over 30% Other Interest Income: $16M - $18M Tax Rate: 27% - 29% 9 © 20
Slide 10: Appendix
Appendix 10 10 © 2025 Azenta, Inc. • All rights reserved
Slide 11: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation Continuing Operations – Total Azenta $ millions except EPS and percentages $ millions, except EPS Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY25 Revenue 142.2 136.4 144.3 150.6 573.4 147.4 143.3 143.9 159.2 593.8 GAAP gross profit 61.8 59.8
Slide 12: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation Continuing Operations – Segments $ millions except percentages Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY25 Multiomics Revenue 62.7 62.2 63.6 66.0 254.6 66.3 63.5 66.2 73.2 269.2 Gross profit 27.9 27.2 28.6 29.5 113.2 29.7 26.6 26.2 31.1 1
Slide 13: Net Income to Adjusted EBITDA Reconciliation
Net Income to Adjusted EBITDA Reconciliation Continuing Operations $ millions except percentages Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY25 Net income (14.3) (137.4) (6.6) (6.7) (164.9) (11.0) (47.7) (48.0) 47.1 (59.5) (Income) Loss from discontinued operations, net of
Slide 14: Calculation of Non-GAAP Organic Revenue
Calculation of Non-GAAP Organic Revenue Continuing Operations Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY25 Revenue 4% 2% 4% 5% 4% 4% 5% (0%) 6% 4% Acquisitions/divestitures (1%) 0% 0% 0% (0%) 0% 0% 0% 0% 0% Currency exchange rates (1%) 0% 1% (0%) (0%) (0%) 1% (2%) (2%) (